The Use of Prophylactic Antibiotics in Isolated Blowout Fractures

Sponsor
University of Arkansas (Other)
Overall Status
Withdrawn
CT.gov ID
NCT01504568
Collaborator
(none)
0
1
2
10
0

Study Details

Study Description

Brief Summary

The purpose of the research is to perform a quality assurance evaluation using randomized prospective analysis the rate of orbital cellulitis as a complication of nonsurgical orbital blowout fracture in patients treated versus not treated with prophylactic antibiotics.

The investigators goal is to show the use of prophylactic antibiotics in orbital blowout fractures does not significantly decrease the rate of orbital cellulitis and is thus not indicated.

Condition or Disease Intervention/Treatment Phase
  • Other: Treatment
N/A

Detailed Description

Orbital fractures are a common occurrence in association with a wide variety of blunt trauma injuries to the face. One type of fracture is that involving the orbital floor, or an isolated blowout fracture. One common current practice is to use prophylactic antibiotics in these cases to prevent the theoretical occurrence of an orbital cellulitis originating from sinus flora, though there is no current standard of care regarding this practice. Many surgeons may elect to not use antibiotics for this very reason.

The use of prophylactic antibiotics in isolated blowout fractures where there is no occlusion of the ostium is not defined, and no prospective controlled study has been undertaken to suggest the most appropriate course of action to take. Our goal in this study is to determine a correct course of action for these patients.

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
The Use of Prophylactic Antibiotics in Isolated Blowout Fractures
Study Start Date :
Jan 1, 2012
Actual Primary Completion Date :
Nov 1, 2012
Actual Study Completion Date :
Nov 1, 2012

Arms and Interventions

Arm Intervention/Treatment
Other: Prophylactic Antibotics

Amoxicillin/clavulanic acid

Other: Treatment
Adults: ≥40 kg:250mg every eight hours Children: <40kg: 20mg/kg/day divided in three doses (up to 250mg) every eight hours Suspension form 250mg/ml
Other Names:
  • Amoxcillin/cavulanic acid
  • No Intervention: Non Treatment

    Subjects will be followed without the use of antibiotics.

    Outcome Measures

    Primary Outcome Measures

    1. Orbital Cellulitis [Two weeks]

      The rate of orbital cellulitis as a complication of nonsurgical orbital blowout fracture in patients treated versus not treated with prophylactic antibiotics.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    5 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Isolated orbital blow out fracture in patients between the ages 5 to 99 years old
    Exclusion Criteria:
    • Involvement of the orbital rim in the floor fracture requiring the use of antibiotics

    • Involvement of the orbital rim in the floor fracture

    • Radiographic evidence of occlusion of the maxillary sinus ostium

    • Determined need for surgical intervention or prior use of synthetic implanted material in or around the involved maxillary sinus

    • Any symptoms of sinonasal disease in the preceding 3 month for any reason

    • Any use of oral or IV antibiotics in the preceding 3 month for any reason

    • Documented allergy to penicillin or amoxicillin prohibiting its use

    • Any currently immunosuppressed state, including actively treated autoimmune disease; use of steroids, immunomodulatory medication, or chemotherapy within the last year; diagnosis of active cancer within the last year

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Arkansas for Medical Sciences Little Rock Arkansas United States 72205

    Sponsors and Collaborators

    • University of Arkansas

    Investigators

    • Principal Investigator: Christopher Westfall, M.D., University of Arkansas
    • Principal Investigator: Bradley Thuro, M.D., University of Arkansas
    • Principal Investigator: John Pemberton, D.O., University of Arkansas

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of Arkansas
    ClinicalTrials.gov Identifier:
    NCT01504568
    Other Study ID Numbers:
    • 134357
    First Posted:
    Jan 5, 2012
    Last Update Posted:
    Nov 9, 2012
    Last Verified:
    Nov 1, 2012

    Study Results

    No Results Posted as of Nov 9, 2012